Loading...

Conformis

Nasdaq:CFMS
Snowflake Description

Imperfect balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CFMS
Nasdaq
$209M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The last earnings update was 80 days ago. More info.


Add to Portfolio Compare Print
  • Conformis has significant price volatility in the past 3 months.
CFMS Share Price and Events
7 Day Returns
-9.4%
NasdaqGS:CFMS
0.9%
US Medical Equipment
-1.2%
US Market
1 Year Returns
199%
NasdaqGS:CFMS
14.6%
US Medical Equipment
3.3%
US Market
CFMS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Conformis (CFMS) -9.4% -24.9% 26.2% 199% -54.5% -
US Medical Equipment 0.9% 1% 12% 14.6% 64% 104.1%
US Market -1.2% 0.8% 0.9% 3.3% 35.9% 41.7%
1 Year Return vs Industry and Market
  • CFMS outperformed the Medical Equipment industry which returned 14.6% over the past year.
  • CFMS outperformed the Market in United States of America which returned 3.3% over the past year.
Price Volatility
CFMS
Industry
5yr Volatility vs Market

CFMS Value

 Is Conformis undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Conformis. This is due to cash flow or dividend data being unavailable. The share price is $3.08.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Conformis's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Conformis's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:CFMS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.64
NasdaqGS:CFMS Share Price ** NasdaqGS (2019-07-19) in USD $3.08
United States of America Medical Equipment Industry PE Ratio Median Figure of 63 Publicly-Listed Medical Equipment Companies 40.94x
United States of America Market PE Ratio Median Figure of 3,082 Publicly-Listed Companies 17.86x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Conformis.

NasdaqGS:CFMS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:CFMS Share Price ÷ EPS (both in USD)

= 3.08 ÷ -0.64

-4.82x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Conformis is loss making, we can't compare its value to the US Medical Equipment industry average.
  • Conformis is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Conformis's expected growth come at a high price?
Raw Data
NasdaqGS:CFMS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.82x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
14.3%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 54 Publicly-Listed Medical Equipment Companies 2.38x
United States of America Market PEG Ratio Median Figure of 2,119 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Conformis, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Conformis's assets?
Raw Data
NasdaqGS:CFMS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.45
NasdaqGS:CFMS Share Price * NasdaqGS (2019-07-19) in USD $3.08
United States of America Medical Equipment Industry PB Ratio Median Figure of 183 Publicly-Listed Medical Equipment Companies 4.34x
United States of America Market PB Ratio Median Figure of 5,248 Publicly-Listed Companies 1.79x
NasdaqGS:CFMS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:CFMS Share Price ÷ Book Value per Share (both in USD)

= 3.08 ÷ 0.45

6.88x

* Primary Listing of Conformis.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Conformis is overvalued based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess Conformis's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Conformis has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CFMS Future Performance

 How is Conformis expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
14.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Conformis expected to grow at an attractive rate?
  • Unable to compare Conformis's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Conformis's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Conformis's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:CFMS Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:CFMS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 14.3%
NasdaqGS:CFMS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 5.8%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.5%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:CFMS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:CFMS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 98 -10 -24 2
2020-12-31 89 -17 -24 5
2019-12-31 82 -11 -28 5
NasdaqGS:CFMS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 91 -23 -39
2018-12-31 90 -27 -43
2018-09-30 88 -37 -45
2018-06-30 78 -36 -50
2018-03-31 77 -35 -48
2017-12-31 78 -38 -54
2017-09-30 79 -42 -57
2017-06-30 79 -43 -58
2017-03-31 80 -49 -60
2016-12-31 80 -49 -58
2016-09-30 77 -58 -57
2016-06-30 72 -60 -61

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Conformis is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Conformis's revenue is expected to grow by 5.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:CFMS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Conformis Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:CFMS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -0.30 -0.26 -0.35 2.00
2020-12-31 -0.35 -0.29 -0.44 5.00
2019-12-31 -0.43 -0.39 -0.46 5.00
NasdaqGS:CFMS Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.64
2018-12-31 -0.74
2018-09-30 -0.83
2018-06-30 -1.00
2018-03-31 -1.05
2017-12-31 -1.24
2017-09-30 -1.34
2017-06-30 -1.36
2017-03-31 -1.42
2016-12-31 -1.39
2016-09-30 -1.38
2016-06-30 -1.51

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Conformis will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Conformis's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Conformis has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CFMS Past Performance

  How has Conformis performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Conformis's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Conformis does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Conformis's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Conformis's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Conformis's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Conformis Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:CFMS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 90.78 -38.95 58.10 15.09
2018-12-31 89.79 -43.37 61.14 16.87
2018-09-30 88.49 -45.35 61.84 17.57
2018-06-30 77.93 -50.39 63.48 17.79
2018-03-31 77.32 -48.42 63.69 17.27
2017-12-31 78.12 -53.58 66.41 17.14
2017-09-30 79.04 -57.46 68.33 17.11
2017-06-30 79.26 -57.75 67.79 17.13
2017-03-31 80.10 -59.71 68.11 16.77
2016-12-31 79.90 -57.59 66.12 16.61
2016-09-30 77.10 -56.84 64.72 17.25
2016-06-30 72.15 -61.18 65.01 17.04
2016-03-31 71.84 -58.02 62.80 17.38
2015-12-31 66.09 -57.25 60.75 17.00
2015-09-30 61.13 -54.39 57.92 16.16
2015-06-30 59.34 -47.68 53.85 16.25
2015-03-31 51.29 -47.33 50.90 15.55
2014-12-31 47.49 -45.72 46.13 15.11
2013-12-31 34.20 -47.89 40.84 13.78

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Conformis has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Conformis has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Conformis improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Conformis's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Conformis has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CFMS Health

 How is Conformis's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Conformis's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Conformis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Conformis's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Conformis's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Conformis Company Filings, last reported 3 months ago.

NasdaqGS:CFMS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 30.39 14.82 18.62
2018-12-31 36.20 14.79 23.63
2018-09-30 43.46 29.75 36.93
2018-06-30 49.17 29.72 46.58
2018-03-31 60.30 29.69 57.28
2017-12-31 46.51 29.67 45.23
2017-09-30 56.91 29.64 54.50
2017-06-30 68.29 29.61 68.43
2017-03-31 79.76 14.72 64.30
2016-12-31 94.06 0.00 65.50
2016-09-30 104.77 0.26 73.32
2016-06-30 115.80 0.33 82.56
2016-03-31 128.10 0.41 103.52
2015-12-31 141.21 0.48 117.19
2015-09-30 155.12 0.55 139.20
2015-06-30 27.54 10.50 14.50
2015-03-31 36.78 10.56 22.94
2014-12-31 49.83 10.62 37.90
2013-12-31 68.96 3.11 54.22
  • Conformis's level of debt (48.8%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (7.8% vs 48.8% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Conformis has less than a year of cash runway based on current free cash flow.
  • Conformis has less than a year of cash runway if free cash flow continues to reduce at historical rates of -25% each year.
X
Financial health checks
We assess Conformis's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Conformis has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CFMS Dividends

 What is Conformis's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Conformis dividends.
If you bought $2,000 of Conformis shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Conformis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Conformis's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:CFMS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:CFMS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Conformis has not reported any payouts.
  • Unable to verify if Conformis's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Conformis's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Conformis has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Conformis's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Conformis afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Conformis has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CFMS Management

 What is the CEO of Conformis's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mark Augusti
COMPENSATION $1,231,541
AGE 53
TENURE AS CEO 2.7 years
CEO Bio

Mr. Mark A. Augusti has been Chief Executive Officer and President at ConforMIS, Inc. since November 14, 2016. Mr. Augusti's 27-year business career has been marked with executive management responsibility in medical technology sales, marketing and general management. Mr. Augusti served as Corporate Vice President and President of Orthopedics & Tissue Technologies at Integra LifeSciences Holdings Corporation from April 2014 to November 11, 2016. He was responsible for the management of LifeSciences Holdings's Spine and Extremities divisions, including strategic direction, portfolio management and evaluation of corporate development opportunities at Integra LifeSciences Holdings Corporation. He has 25 years of executive management and strategic decision-making experience at leading organizations. Mr. Augusti served as the Chief Executive Officer of Bioventus Inc. from May 2012 to August 2013. Mr. Augusti served as the President of Clinical Therapies/Biologics at Smith & Nephew plc. He served as the President of Orthopaedic Trauma and Clinical Therapies at Smith & Nephew plc since February 9, 2006 and Smith & Nephew Orthopaedics Ltd. since February 2006. He served as the President of Biologics & Spine at Smith & Nephew plc and President of Biologics from January 2008 to April 2012. Mr. Augusti served as General Manager of Trauma Division of Smith & Nephew AHP, Inc. (formerly, Smith & Nephew, Inc.) from April 2005 to February 2006. He served as Senior Vice President Of Trauma Division of Smith & Nephew, Inc. from April 2005 to February 2006. He started his career in sales with GE Medical Systems and spent 13 years (from 1987 to 2000) there in a number of roles based in the US and Asia. He joined Smith & Nephew in April 2003 as Vice President of Global Marketing of Trauma Division and served until April 2005. Mr. Augusti served as Vice President at JPMorgan Chase & Co. from 2000 to 2003 and held various sales, marketing and strategic management roles, both in the U.S. GE Medical Systems from 1987 to 2000. He has been a Director of ConforMIS, Inc. since November 28, 2016. He serves as a Director at View Medical, Inc. He served as an Independent Director of Hutchinson Technology Inc. from February 2010 to May 2012. He served as a Director of Bioventus from May 2012 to August 2013. He serves as a Member of the Orthopaedic Institute of Medicine (OIOM) and Council of the American Orthopaedic Association. Mr. Augusti holds Master of Business Administration from UCLA's Anderson Graduate School of Management and B.S Degree in Computer Science and Economics from Duke University.

CEO Compensation
  • Mark's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Mark's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Conformis management team in years:

2.5
Average Tenure
54
Average Age
  • The tenure for the Conformis management team is about average.
Management Team

Mark Augusti

TITLE
CEO, President & Director
COMPENSATION
$1M
AGE
53
TENURE
2.7 yrs

Paul Weiner

TITLE
CFO & Treasurer
COMPENSATION
$649K
AGE
55
TENURE
5.3 yrs

Ed Kilgallen

TITLE
Vice President of Operations
TENURE
1.9 yrs

John Slamin

TITLE
Senior Vice President of Product Engineering
AGE
65
TENURE
11.8 yrs

Manny Nyakako

TITLE
Senior Vice President of Quality & Regulatory Affairs
TENURE
2.3 yrs

Daniel Steines

TITLE
Consultant
COMPENSATION
$889K
AGE
50
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the Conformis board of directors in years:

10.4
Average Tenure
55
Average Age
  • The average tenure for the Conformis board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Ken Fallon

TITLE
Chairman of the Board
COMPENSATION
$178K
AGE
80
TENURE
4.4 yrs

Mark Augusti

TITLE
CEO, President & Director
COMPENSATION
$1M
AGE
53
TENURE
2.7 yrs

Brad Langdale

TITLE
Director
COMPENSATION
$144K
AGE
55
TENURE
11.2 yrs

Thomas Thornhill

TITLE
Member of Scientific Advisory Board

Thomas Minas

TITLE
Member of Scientific Advisory Board

Wolfgang Fitz

TITLE
Member of Scientific Advisory Board

Richard Scott

TITLE
Member of Scientific Advisory Board
TENURE
10.6 yrs

Amar Ranawat

TITLE
Member of the Scientific Advisory Board
TENURE
10.4 yrs

Anil Ranawat

TITLE
Member of the Scientific Advisory Board
TENURE
10.4 yrs

Brian McKeon

TITLE
Member of the Scientific Advisory Board
TENURE
10.4 yrs
Who owns this company?
Recent Insider Trading
  • Conformis individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
11. Jul 19 Sell Archon Capital Management LLC Company 09. Jul 19 11. Jul 19 -702,295 $3.83 $-2,659,164
03. Jul 19 Sell Paul Weiner Individual 02. Jul 19 02. Jul 19 -10,764 $4.15 $-44,671
03. Jul 19 Sell Mark Augusti Individual 02. Jul 19 02. Jul 19 -23,860 $4.15 $-99,019
17. May 19 Sell Paul Weiner Individual 16. May 19 16. May 19 -3,303 $3.53 $-11,660
17. May 19 Sell Mark Augusti Individual 16. May 19 16. May 19 -6,807 $3.53 $-24,029
08. May 19 Sell Paul Weiner Individual 07. May 19 07. May 19 -12,612 $2.72 $-34,326
08. May 19 Sell Patricia Davis Individual 07. May 19 07. May 19 -5,794 $2.72 $-15,769
08. May 19 Sell Mark Augusti Individual 07. May 19 07. May 19 -25,477 $2.72 $-69,336
07. Mar 19 Sell Patricia Davis Individual 05. Mar 19 05. Mar 19 -6,266 $1.26 $-7,895
07. Feb 19 Sell Paul Weiner Individual 05. Feb 19 05. Feb 19 -2,294 $0.74 $-1,698
04. Jan 19 Buy Archon Capital Management LLC Company 02. Jan 19 02. Jan 19 560,000 $0.41 $229,600
07. Dec 18 Sell Mark Augusti Individual 04. Dec 18 04. Dec 18 -2,706 $0.69 $-1,854
17. Oct 18 Sell Paul Weiner Individual 16. Oct 18 16. Oct 18 -833 $0.94 $-783
10. Aug 18 Sell Paul Weiner Individual 08. Aug 18 08. Aug 18 -2,529 $0.91 $-2,301
10. Aug 18 Sell Daniel Steines Individual 08. Aug 18 08. Aug 18 -1,542 $0.91 $-1,403
10. Aug 18 Sell Mark Augusti Individual 08. Aug 18 08. Aug 18 -7,618 $0.91 $-6,932
X
Management checks
We assess Conformis's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Conformis has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CFMS News

Simply Wall St News

Read This Before Buying Conformis, Inc. (NASDAQ:CFMS) Shares

So we'll take a look at whether insiders have been buying or selling shares in Conformis, Inc. … Insiders at Conformis Have Sold Stock Recently The last quarter saw substantial insider selling of Conformis shares. … Insider Ownership of Conformis I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders.

Simply Wall St -

The Conformis (NASDAQ:CFMS) Share Price Is Up 139% And Shareholders Are Boasting About It

See our latest analysis for Conformis Given that Conformis didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … When a company doesn't make profits, we'd generally expect to see good revenue growth. … While that revenue growth is pretty good the share price performance outshone it, with a lift of 139% as mentioned above.

Simply Wall St -

What Does Conformis, Inc.'s (NASDAQ:CFMS) Balance Sheet Tell Us About It?

(NASDAQ:CFMS) is a small-cap stock with a market capitalization of US$158m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health.

Simply Wall St -

What Do Analysts Think About Conformis, Inc.'s (NASDAQ:CFMS) Earnings Trajectory?

(NASDAQ:CFMS) released its most recent earnings announcement, which … company earnings became less negative compared to the previous year's level … as a result of recent tailwinds

Simply Wall St -

Conformis, Inc. (NASDAQ:CFMS): Cash Is King

I’ve analysed below, the health and outlook of Conformis’s cash flow, which will help you understand the stock from a cash standpoint. … What is Conformis's cash yield. … Conformis’s free cash flow (FCF) is the level of cash flow the business generates from its operational activities, after it reinvests in the company as capital expenditure

Simply Wall St -

Is Conformis, Inc. (NASDAQ:CFMS) A Financially Sound Company?

(NASDAQ:CFMS) is a small-cap stock with a market capitalization of US$29m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … So, understanding the company's financial health becomes

Simply Wall St -

What Kind Of Investor Owns Most Of Conformis, Inc. (NASDAQ:CFMS)?

Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … With a market capitalization of US$30m, Conformis is a small cap stock, so it might not be well known by many institutional investors. … institutional investors have bought into the company.

Simply Wall St -

Conformis Inc's (NASDAQ:CFMS) Most Important Factor To Consider

If you are currently a shareholder in Conformis Inc (NASDAQ:CFMS), or considering investing in the stock, you need to examine how the business generates cash, and how it is reinvested. … I’ve analysed below, the health and outlook of Conformis’s cash flow, which will help you understand the stock from a cash standpoint. … The two ways to assess whether Conformis’s FCF is sufficient, is to compare the FCF yield to the market index yield, as well as determine whether the top-line operating cash flows will continue to grow

Simply Wall St -

Are Conformis Inc's (NASDAQ:CFMS) Interest Costs Too High?

Investors are always looking for growth in small-cap stocks like Conformis Inc (NASDAQ:CFMS), with a market cap of US$56.86m. … However, an important fact which most ignore is: how financially healthy is the business? … especially ones that are currently loss-making,

Simply Wall St -

Are Conformis Inc (NASDAQ:CFMS) Shareholders Getting A Good Deal?

I’ve analysed below, the health and outlook of Conformis’s cash flow, which will help you understand the stock from a cash standpoint. … Conformis’s free cash flow (FCF) is the level of cash flow the business generates from its operational activities, after it reinvests in the company as capital expenditure. … There are two methods I will use to evaluate the quality of Conformis’s FCF: firstly, I will measure its FCF yield relative to the market index yield; secondly, I will examine whether its operating cash flow will continue to grow into the future, which will give us a sense of sustainability.

Simply Wall St -

CFMS Company Info

Description

Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides Conformis Hip System, a hip replacement product; and iJigs, a customized single-use patient-specific instrumentation. The company markets and sells its products to hospitals and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore, Hong Kong, Malaysia, Monaco, Hungary, Spain, and Australia Conformis, Inc. was founded in 2004 and is headquartered in Billerica, Massachusetts.

Details
Name: Conformis, Inc.
CFMS
Exchange: NasdaqGS
Founded: 2004
$209,020,470
67,863,789
Website: http://www.conformis.com
Address: Conformis, Inc.
600 Technology Park Drive,
Billerica,
Massachusetts, 01821,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS CFMS Common Stock Nasdaq Global Select US USD 01. Jul 2015
DB 308 Common Stock Deutsche Boerse AG DE EUR 01. Jul 2015
Number of employees
Current staff
Staff numbers
265
Conformis employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/22 03:32
End of day share price update: 2019/07/19 00:00
Last estimates confirmation: 2019/07/03
Last earnings filing: 2019/05/03
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.